سعر راسبيلوسين ٤٠٠ مجم ١٠ أقراص 400 مجم 2026

Moxifloxacin 400 mg film-coated tablets, a fluoroquinolone antibacterial; pack of 10 tablets (Organo Pharma, Egypt).

• Community-acquired pneumonia caused by susceptible bacteriaPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Uncomplicated and complicated skin and skin structure infectionsPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Complicated intra-abdominal infectionsPopulation: AdultsDailyMed (U.S. National Library of Medicine)

• Most common (3% or more): nausea, diarrhoea, headache and dizziness.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• History of hypersensitivity to moxifloxacin or any other quinolone antibacterial.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: disabling and potentially irreversible serious reactions including tendinitis/tendon rupture, peripheral neuropathy and CNS effects; discontinue immediately and avoid fluoroquinolones in patients who experience them.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• May exacerbate muscle weakness in myasthenia gravis; avoid in patients with a history of myasthenia gravis.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• QT prolongation and isolated torsade de pointes; avoid with known QT prolongation, uncorrected hypokalaemia/hypomagnesaemia, clinically significant bradycardia, acute myocardial ischaemia and class IA/III antiarrhythmics.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Multivalent cations (antacids, sucralfate, iron, zinc, multivitamins)Decreased moxifloxacin absorption; separate doses (4 h before or 8 h after).DailyMed (U.S. National Library of Medicine)
• WarfarinAnticoagulant effect may be enhanced; monitor prothrombin time/INR and bleeding.DailyMed (U.S. National Library of Medicine)
• Class IA and class III antiarrhythmicsProarrhythmic (QT) effect may be enhanced; avoid concomitant use.DailyMed (U.S. National Library of Medicine)

• No human data establishing a drug-associated risk; based on animal studies moxifloxacin may cause fetal harm; advise pregnant women of the potential risk.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Not known whether present in human milk; excreted at very low levels in rat milk; weigh benefits of breastfeeding against maternal need and potential infant effects.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Moxifloxacin: Bactericidal; inhibits bacterial topoisomerase II (DNA gyrase) and topoisomerase IV required for DNA replication, transcription, repair and recombination (US label).